List of works - Sengeziwe Sibeko

CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck

scientific article

Contraception and pregnancy in microbicide trials

scientific article

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial

scientific article

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

scientific article

From the Laboratory to Clinical Trials and Back Again: Lessons Learned from HIV Prevention Trials ⬇️

scientific article published on December 13, 2012

HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial

scientific article

How can we design better vaccines to prevent HIV infection in women?

scientific article

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

scientific article

Localized cyclical variations in immunoproteins in the female genital tract and the implications on the design and assessment of mucosal infection and therapies

scientific article

Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive

scientific article published on 22 April 2015

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

scientific article

Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial

scientific article

Preventing HIV infection in women: a global health imperative

scientific article

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies ⬇️

scientific article published on April 24, 2013

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial

scientific article

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial

scientific article published on 23 August 2012

Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial

scientific article

The development of CD4 binding site antibodies during HIV-1 infection

scientific article

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

scientific article

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial ⬇️

scientific article published on March 5, 2013

List of works by Sengeziwe Sibeko

CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck

Contraception and pregnancy in microbicide trials

Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

From the Laboratory to Clinical Trials and Back Again: Lessons Learned from HIV Prevention Trials ⬇️

HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial

How can we design better vaccines to prevent HIV infection in women?

Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.

Localized cyclical variations in immunoproteins in the female genital tract and the implications on the design and assessment of mucosal infection and therapies

Lower concentrations of chemotactic cytokines and soluble innate factors in the lower female genital tract associated with the use of injectable hormonal contraceptive

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

Preservation HIV-1-specific IFNγ+ CD4+ T-cell responses in breakthrough infections after exposure to tenofovir gel in the CAPRISA 004 microbicide trial

Preventing HIV infection in women: a global health imperative

Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies ⬇️

Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial

Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial

Sensitive tenofovir resistance screening of HIV-1 from the genital and blood compartments of women with breakthrough infections in the CAPRISA 004 tenofovir gel trial

The development of CD4 binding site antibodies during HIV-1 infection

The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection

Women with Pregnancies Had Lower Adherence to 1% Tenofovir Vaginal Gel as HIV Preexposure Prophylaxis in CAPRISA 004, a Phase IIB Randomized-Controlled Trial ⬇️